Biogen Inc.
BIIB · Healthcare
$216.04
Loading chart…
News
Latest headlines for this stock
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Pharmaceuticals reported Q2 2026 earnings that missed EPS estimates ($4.73 vs $4.79 consensus) but beat revenue expectations ($3.33B vs $3.23B consensus). The company raised full-year 2026 revenue guidance to $13.10-$13.20B. However, analyst estimates have trended downward over the past month despite the stock gaining 14.4%. The company received a Zacks Rank #3 (Hold) rating with a VGM Score of D, suggesting in-line returns ahead.
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Canada's Drug Agency (CDA-AMC) has issued a final positive recommendation supporting public reimbursement of LEQEMBI (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease. The recommendation follows reconsideration and will proceed to negotiations through the pan-Canadian Pharmaceutical Alliance, with individual reimbursement decisions to follow from provincial and territorial drug plans.
Biogen Completes Acquisition of RayThera Inc.
Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule immunology therapies. The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program entering Phase 1 development in July 2026. The company views this as part of its strategic growth in immunology and its open innovation model.